Lisata Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Lisata Therapeutics
LSTA Stock  USD 1.97  0.09  4.37%   
Lisata Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Lisata Therapeutics' valuation are provided below:
Gross Profit
1.1 M
Market Capitalization
17.4 M
Enterprise Value Revenue
0.3782
Revenue
1.1 M
Earnings Share
(2.13)
We have found one hundred twenty available fundamental ratios for Lisata Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Lisata Therapeutics last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 29.6 M, whereas Enterprise Value is forecasted to decline to about 6.8 M.

Lisata Therapeutics Total Revenue

1.09 Million

Check Lisata Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lisata Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 190.1 K, Interest Expense of 2.4 M or Selling General Administrative of 7.5 M, as well as many indicators such as Price To Sales Ratio of 27.12, Dividend Yield of 0.76 or PTB Ratio of 0.79. Lisata financial statements analysis is a perfect complement when working with Lisata Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Lisata Stock
Check out the analysis of Lisata Therapeutics Correlation against competitors.
For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.

Lisata Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets43.2 M40.3 M61.9 M
Slightly volatile
Short and Long Term Debt Total149.7 K157.6 K3.4 M
Slightly volatile
Other Current Liabilities3.9 M4.8 M5.8 M
Slightly volatile
Total Current Liabilities8.4 M6.5 M10.5 M
Slightly volatile
Property Plant And Equipment Net78.7 K82.8 K5.1 M
Slightly volatile
Accounts Payable2.1 M1.5 M2.2 M
Pretty Stable
Non Current Assets Total463.2 K487.6 K20.4 M
Slightly volatile
Net Receivables1.6 M1 M1.2 M
Slightly volatile
Common Stock Shares Outstanding10.1 M9.6 M2.9 M
Slightly volatile
Liabilities And Stockholders Equity43.2 M40.3 M61.9 M
Slightly volatile
Non Current Liabilities Total78.7 K82.8 K10 M
Slightly volatile
Other Current Assets3.6 M2.8 M5.4 M
Slightly volatile
Other Stockholder Equity697.6 M664.4 M429.3 M
Slightly volatile
Total Liabilities6.2 M6.5 M20.4 M
Slightly volatile
Total Current Assets25.1 M39.8 M40.4 M
Slightly volatile
Short Term Debt149.7 K157.6 K1.3 M
Slightly volatile
Common Stock6.8 K7.2 K34.9 K
Slightly volatile
Intangible Assets209.8 K220.8 K5.9 M
Slightly volatile
Cash11.5 M18.6 M18.5 M
Pretty Stable
Cash And Short Term Investments20.7 M35.9 M34.5 M
Slightly volatile
Good Will12.1 M8.1 M8.8 M
Pretty Stable
Short Term Investments18.5 M17.3 M20.5 M
Slightly volatile
Current Deferred Revenue1.8 M2.9 M2.6 M
Pretty Stable
Inventory4.5 M4.5 M4.4 M
Very volatile
Other Liabilities852.4 K561.6 K1.1 M
Slightly volatile
Net Tangible Assets111.4 M106.1 M57.6 M
Slightly volatile
Net Invested Capital51.5 M34 M42.1 M
Pretty Stable
Capital Stock14.2 K7.2 K13.3 K
Pretty Stable
Non Current Liabilities Other61.6 K64.8 K862.4 K
Slightly volatile
Net Working Capital50.9 M33.3 M42.1 M
Pretty Stable
Property Plant Equipment711.7 K903.9 K463.6 K
Slightly volatile
Capital Lease Obligations117.1 K123.3 K347.6 K
Slightly volatile
Property Plant And Equipment Gross583.7 K760.1 K451.1 K
Slightly volatile

Lisata Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative7.5 M13.9 M11.3 M
Pretty Stable
Other Operating Expenses23.9 M26.9 M35 M
Slightly volatile
Research Development16.1 M13 M15.7 M
Pretty Stable
Cost Of Revenue148.8 K156.6 K4.3 M
Slightly volatile
Total Operating Expenses19.4 M26.9 M31 M
Pretty Stable
Selling And Marketing Expenses13.3 M11.5 M15.9 M
Slightly volatile
Reconciled Depreciation132 K200.1 K174.8 K
Slightly volatile

Lisata Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow27.3 M26 M21.2 M
Slightly volatile
Depreciation190.1 K200.1 K813.3 K
Slightly volatile
End Period Cash Flow11.3 M18.6 M19.9 M
Very volatile
Stock Based Compensation2.8 M1.5 M2.5 M
Slightly volatile
Dividends Paid18.1 M17.2 M12.9 M
Slightly volatile
Issuance Of Capital Stock58.1 K61.2 K6.8 M
Pretty Stable
Change To Netincome5.5 M5.2 M2.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio27.1228.5416.8099
Slightly volatile
Dividend Yield0.760.730.6118
Slightly volatile
Days Sales Outstanding390378213
Slightly volatile
Average Payables4.6 M4.4 M4.3 M
Slightly volatile
Stock Based Compensation To Revenue1.811.93.8274
Slightly volatile
Capex To Depreciation4.994.751.8875
Slightly volatile
EV To Sales9.5610.066.9035
Slightly volatile
Inventory Turnover0.08120.08552.8694
Slightly volatile
Days Of Inventory On Hand4.6 K4.4 K3.1 K
Slightly volatile
Payables Turnover0.06750.0716.2391
Slightly volatile
Sales General And Administrative To Revenue10.510.877.0908
Slightly volatile
Average Inventory5.7 M2.9 M4 M
Slightly volatile
Research And Ddevelopement To Revenue10.7110.26.9204
Slightly volatile
Capex To Revenue0.08820.09290.0913
Very volatile
Cash Per Share4.14.3186.2374
Slightly volatile
Days Payables Outstanding5.6 K5.3 K3.2 K
Slightly volatile
Income Quality0.920.870.7925
Slightly volatile
Intangibles To Total Assets0.00470.00490.1186
Slightly volatile
Current Ratio3.025.545.7575
Slightly volatile
Receivables Turnover0.951.028.2031
Slightly volatile
Capex Per Share0.06010.0633111
Slightly volatile
Average Receivables128.1 K134.8 K820 K
Slightly volatile
Revenue Per Share0.130.145.2 K
Slightly volatile
Interest Debt Per Share0.0180.01891.5 K
Slightly volatile
Debt To Assets0.00430.00450.0866
Slightly volatile
Graham Number204229250
Slightly volatile
Operating Cycle281296654
Very volatile
Days Of Payables Outstanding5.6 K5.3 K3.2 K
Slightly volatile
Ebt Per Ebit1.21.071.0577
Pretty Stable
Long Term Debt To Capitalization0.30.410.3302
Very volatile
Total Debt To Capitalization0.0050.00530.2008
Slightly volatile
Quick Ratio2.965.545.6788
Slightly volatile
Cash Ratio1.32.62.4606
Slightly volatile
Days Of Inventory Outstanding4.6 K4.4 K3.1 K
Slightly volatile
Days Of Sales Outstanding390378213
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.90.911.0494
Slightly volatile
Fixed Asset Turnover16.7715.979.8046
Slightly volatile
Debt Ratio0.00430.00450.0866
Slightly volatile
Price Sales Ratio27.1228.5416.8099
Slightly volatile
Asset Turnover0.03120.03290.244
Slightly volatile
Gross Profit Margin0.130.140.1319
Slightly volatile

Lisata Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap29.6 M15.1 M21.6 M
Slightly volatile
Enterprise Value6.8 M7.1 M11.8 M
Slightly volatile

Lisata Fundamental Market Drivers

Lisata Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lisata Therapeutics Financial Statements

Lisata Therapeutics stakeholders use historical fundamental indicators, such as Lisata Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Lisata Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lisata Therapeutics' assets and liabilities are reflected in the revenues and expenses on Lisata Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lisata Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.9 M1.8 M
Total Revenue1.1 M1.1 M
Cost Of Revenue156.6 K148.8 K
Stock Based Compensation To Revenue 1.90  1.81 
Sales General And Administrative To Revenue 10.87  10.50 
Research And Ddevelopement To Revenue 10.20  10.71 
Capex To Revenue 0.09  0.09 
Revenue Per Share 0.14  0.13 
Ebit Per Revenue(20.17)(21.18)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft
When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:
How To Invest In Lisata
Details
Is Lisata Stock a good investment?
Details
What is Lisata Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Lisata Therapeutics Correlation against competitors.
For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.13)
Revenue Per Share
0.125
Return On Assets
(0.42)
Return On Equity
(0.72)
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY